Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03294603 · ClinicalTrials.gov registry record · Phase 1
Radiolabeled Study of CC-220 in Healthy Male Subjects
A Phase 1 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT03294603 is a Phase 1 study that has completed, run by Celgene. The registered enrollment target is 6 participants.
The verdict
NCT03294603, a Phase 1 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This is a single-center, open-label study to characterize the biotransformation and excretion of \[14C\]-CC-220 in healthy male subjects. Each subject will participate in screening, a treatment phase (including baseline), and a follow-up phone call. Subjects will be screened for eligibility. Subjects who have met all inclusion criteria and none of the exclusion criteria at screening will return to the study site on Day -1, and will be domiciled at the study site from Day -1 to Day 10. On Day 1, subjects will receive a single oral dose of 1 mg \[14C\]-CC-220 under fasted conditions. Blood, urine, and fecal samples will be collected throughout the study for pharmacokinetic (PK; inclusive of metabolite profiling / characterization), mass balance, and/or clinical laboratory assessments. Safety will be monitored throughout the study. Subjects will be discharged from the study site on Day 10 following completion of the scheduled study procedures and satisfactory safety review. Subjects will participate in a follow-up phone call within 5 to 7 days following discharge.
Interventions
- DRUG CC-220
- RADIATION [14C]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2017-09-11 |
| Est. Completion | 2017-10-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03294603
The ClinicalTrials.gov registry entry for NCT03294603 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CC-220 is the first listed.
NCT03294603 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03294603 about?
NCT03294603 is a clinical study titled "Radiolabeled Study of CC-220 in Healthy Male Subjects". This is a single-center, open-label study to characterize the biotransformation and excretion of \[14C\]-CC-220 in healthy male subjects. Each subject will participate in screening, a treatment phase (including baseline), and a follow-up phone call. Subjects will be screened for eligibility. Subject...
What is the current status of trial NCT03294603?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2017-09-11. Estimated completion is 2017-10-16.
What interventions are being tested in trial NCT03294603?
The interventions under investigation include: CC-220 (DRUG), [14C] (RADIATION).
Who is sponsoring clinical trial NCT03294603?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.